Preoperative Axillary Ultrasound in the Selection of Patients With a Heavy Axillary Tumor Burden in Early-Stage Breast Cancer: What Leads to False-Positive Results?

2018 ◽  
Vol 37 (6) ◽  
pp. 1357-1365 ◽  
Author(s):  
Ying Zhu ◽  
Wei Zhou ◽  
Xiao-hong Jia ◽  
Ou Huang ◽  
Wei-wei Zhan
Keyword(s):  
Breast Cancer ◽  
False Positive ◽  
Early Stage ◽  
Tumor Burden ◽  
Early Stage Breast Cancer ◽  
Axillary Ultrasound ◽  
Positive Results ◽  
Selection Of Patients ◽  
Selection Of

Diagnostic Accuracy of Axillary Ultrasound in Early–Stage Breast Cancer

2018 ◽  
Vol 81 (5) ◽  
pp. 421-425
Author(s):  
Tugba Han Yilmaz ◽  
Hasan Yerli ◽  
Baha Arslan ◽  
Varlık Erol ◽  
Huseyin Gulay
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Axillary Ultrasound

scholarly journals The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer

2015 ◽  
Vol 18 (4) ◽  
pp. 541-546 ◽  
Author(s):  
Louis P. Garrison ◽  
Joseph B. Babigumira ◽  
Anthony Masaquel ◽  
Bruce C.M. Wang ◽  
Deepa Lalla ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Economic Burden ◽  
False Positive ◽  
Early Stage ◽  
False Negative ◽  
Early Stage Breast Cancer ◽  
Test Results ◽  
Her2 Testing

Tolerability and cardiac safety of neo/adjuvant trastuzumab-based chemotherapy regimens for HER2+ breast cancer: A single institution experience.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11508-e11508
Author(s):  
Potjana Jitawatanarat ◽  
Ellen Kossoff ◽  
Grazyna Riebandt ◽  
Ellis Glenn Levine ◽  
Tracey L. O'Connor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Cardiac Safety ◽  
Cardiac Events ◽  
Adjuvant Trastuzumab ◽  
Her2 Breast Cancer ◽  
Comorbidity Index ◽  
Grade 3 ◽  
Selection Of Patients ◽  
Selection Of

e11508 Background: Docetaxel/carboplatin/trastuzumab (H) (TCaH) and doxorubicin/cyclophosphamide/paclitaxel/H (AC-TH) and its variants are recommended by standard guidelines for neoadjuvant and adjuvant treatments for HER2+ breast cancer. Docetaxel/cyclophosphamide/H (TCyH) has also been used in clinical practice. Tolerability and cardiac safety among these regimens have not been well described. Methods: We retrospectively reviewed HER2+ early stage breast cancer who received neo/adjuvant H at RPCI between 2004-2011. Acute toxicities of different regimens (AC-TH and its variants, TCaH, TCyH) were evaluated. Cardiac events were defined as symptomatic congestive heart failure (CHF) and/or asymptomatic decline of ejection fraction (EF) that resulted in holding H. Results: 177 patients were identified (AC-TH=114, TCaH=39, TCyH=24). Patients who received AC-TH were younger, had less comorbidity, including cardiac history, and received less GCSF support. AC-TH regimens were associated with more febrile neutropenia (FN), grade 3-4 neutropenia, and dose delay (Table). Overall cardiac events were observed in 18% (anthracyclines 14% vs non-anthracyclines 9%; p=0.346). Termination of H was not significantly different between patients treated with anthracyclines (4%) vs non-anthracyclines (2%), nor was the CHF rate (4% vs 6%). Median absolute EF decline was also similar (5% vs 4%). After adjustment for age ≥65, cardiac history, baseline EF <55%, and Charlson Comorbidity Index, patients treated with anthracyclines showed a trend toward increased cardiac events (OR 4.53, 95% CI 0.99-20.5; p=0.05) in multivariate analysis. Conclusions: Although physician selection of patients for trastuzumab directed therapy lessens overall toxicity, the acute toxicity and cardiac event rate among those considered the most fit remains considerable when an anthracycline is introduced. [Table: see text]

scholarly journals Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer

2016 ◽  
Vol 264 (6) ◽  
pp. 1098-1102 ◽  
Author(s):  
Natalia S. Tucker ◽  
Amy E. Cyr ◽  
Foluso O. Ademuyiwa ◽  
Adel Tabchy ◽  
Krystl George ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Axillary Ultrasound ◽  
Lymph Node Disease ◽  
Node Disease ◽  
Clinically Significant
Sign in / Sign up

Export Citation Format

Share Document